Effect of a single, oral, high-dose vitamin D supplementation on endothelial function in patients with peripheral arterial disease: a randomised controlled pilot study

Eur J Vasc Endovasc Surg. 2012 Sep;44(3):307-12. doi: 10.1016/j.ejvs.2012.06.023. Epub 2012 Jul 24.

Abstract

Objective: Apart from its role in bone metabolism, vitamin D may also influence cardiovascular disease. The objective of this study was: (1) to determine the effect of a single, oral, high-dose vitamin D supplementation on endothelial function and arterial stiffness in patients with peripheral arterial disease (PAD) and (2) to investigate the impact of this supplementation on coagulation and inflammation parameters.

Methods: In this double-blind, placebo-controlled, interventional pilot study, we screened 76 Caucasian patients with PAD for vitamin D deficiency. Sixty-two were randomised to receive a single, oral supplementation of 100,000 IU vitamin D3 or placebo. At baseline and after 1 month, we measured serum vitamin D and parathormone levels, and surrogate parameters for cardiovascular disease.

Results: Sixty-five of 76 patients (86%) had low 25-hydroxyvitamin D levels (<30 ng ml(-1)); of those, 62 agreed to participate in the study. At baseline, only parathormone was related to vitamin D. In supplemented patients, vitamin D levels increased from 16.3 ± 6.7 to 24.3 ± 6.2 ng ml(-1) (P < 0.001), with wide variations between single patients; in the placebo group vitamin levels did not change. Seasonal factors accounted for a decrease of vitamin D levels by 8 ng ml(-1) between summer and winter. After 1 month, none of the measured parameters was influenced by vitamin substitution.

Conclusion: In this pilot study, most patients with PAD were vitamin D deficient. Vitamin D supplementation increased serum 25-hydroxyvitamin D without influencing endothelial function, arterial stiffness, coagulation and inflammation parameters, although the study was underpowered for definite conclusions.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Blood Coagulation / drug effects
  • Cholecalciferol / administration & dosage*
  • Cholecalciferol / blood
  • Dietary Supplements*
  • Double-Blind Method
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology
  • Female
  • Hemodynamics / drug effects
  • Humans
  • Inflammation Mediators / blood
  • Linear Models
  • Male
  • Middle Aged
  • Parathyroid Hormone / blood
  • Peripheral Arterial Disease / blood
  • Peripheral Arterial Disease / drug therapy*
  • Peripheral Arterial Disease / physiopathology
  • Pilot Projects
  • Seasons
  • Switzerland
  • Time Factors
  • Treatment Outcome
  • Vascular Stiffness / drug effects
  • Vitamin D / analogs & derivatives
  • Vitamin D / blood
  • Vitamin D Deficiency / blood
  • Vitamin D Deficiency / drug therapy*
  • Vitamin D Deficiency / physiopathology

Substances

  • Biomarkers
  • Inflammation Mediators
  • PTH protein, human
  • Parathyroid Hormone
  • Vitamin D
  • Cholecalciferol
  • 25-hydroxyvitamin D